SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJTs steep slide to new lows is drawing bearish discussion, with traders linking the selloff to concerns about Trumps political standing and the approaching midterms, as well as the companys weak business fundamentals. Some see the decline as a possible trading opportunity, but negative sentiment dominates.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazons sharp rally is drawing attention after Morgan Stanley named it a top pick, citing stronger expected AWS growth and its AI opportunity. Many traders welcomed the upgrade and saw room for further gains, while others questioned whether the move would hold ahead of earnings and watched for resistance.

Cerebras Systems, Inc. engages in the designing and provision of processors for artificial intelligence (AI) training and inference. Its products include inference, Wafer Scale Engine, AI supercomputers, AI model services, cloud, systems, and processors. The company was founded by Sean Lie, Andrew D. Feldman, Gary Lauterbach, Michael James, and Jean Philippe Fricker in 2015 and is headquartered in Sunnyvale, CA.

Cerebras Systems Inc - Ordinary Shares - Class A

Cerebras Systems Inc

Cerebras steep slide to post-IPO lows dominates discussion, with traders citing newly unlocked shares and insider selling, TD Cowens price-target cut, and concerns about valuation, growth and customer concentration amid weakness in AI-related stocks. Bearish calls for more downside contrast with buyers arguing the shares are oversold and adding on dips.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is drawing attention amid a broad semiconductor selloff and concerns about whether AI infrastructure spending can generate sustainable returns; traders also blame CEO Hock Tans remarks likening some AI investing to gambling for adding to uncertainty. Bulls view the pullback as a buying opportunity based on custom-chip demand, while bears worry about AI financing risks and the stocks persistent underperformance.

NuScale Power Corp. provides proprietary and innovative advanced small modular reactor (SMR) nuclear technology, with a mission to help power the global energy transition by delivering safe, scalable, and reliable carbon-free energy. Its products include VOYGR SMR Plants and Energy Exploration (E2) Centers. The company was founded by José N. Reyes in 2007 and is headquartered in Corvallis, OR.

NuScale Power Corporation - Ordinary Shares - Class A

NuScale Power Corp

NuScale shares are under pressure after UBS downgraded the stock, citing long commercialization timelines, limited firm customer commitments and projected cash burn. Traders are debating whether the selloff reflects real execution risks or an overly bearish analyst call, with some buying the dip on the long-term nuclear-power thesis.

CleanSpark, Inc. is a bitcoin mining technology company, which engages in the management of data centers. Its operations include College Park, Norcross, Washington, Sandersville, Dalton, and Massena. The company was founded by S. Matthew Schultz and Bryan Huber on October 15, 1987 and is headquartered in Henderson, NV.

Cleanspark Inc

A sharp selloff in CleanSpark shares, amid weakness across bitcoin miners and concerns about debt costs, management and the AI/data-center pivot, is driving discussion. Traders are split between expecting further declines and buying what they see as an oversold dip, with some long-term holders citing the Meta-backed data-center plans as a counterpoint.

CoreWeave, Inc. engages in the powers of the creation and delivery of the intelligence that drives innovation. It offers a solution used by organizations of all sizes that require sophisticated AI computing, from the largest of enterprises to small, well-funded start-ups. The company was founded by Michael Intrator, Brian Venturo, Peter Salanki, and Brannin McBee on September 21, 2017 and is headquartered in Livingston, NJ.

CoreWeave Inc. - Ordinary Shares - Class A

CoreWeave Inc

CoreWeaves sharp selloff has focused attention on its debt load, borrowing costs and ability to finance its AI infrastructure expansion amid broader doubts about neocloud economics. Traders are split between bargain-buying and short-squeeze hopes and concern about further downside or dilution; a Goldman Sachs upgrade failed to sustain a rebound.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Bitcoin and broader crypto-market volatility, including selloffs and leveraged liquidations, dominate discussion as traders say COIN is falling sharply and often underperforming even when Bitcoin steadies. Bulls are buying the dip and citing hopes around earnings, while bears question the stocks weakness and warn of further downside.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on AbCelleras ABCL635 Phase 2 data for menopausal hot flashes, with traders focused on whether conference updates add evidence on durability, safety and patient outcomes beyond the encouraging topline results. Bullish traders see the data as validation of the companys pipeline, while others caution that expectations may be high and the presentation could offer little new information or prompt profit-taking.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is drawing attention after a sharp memory-stock selloff amid weakness in Korean markets, worries about Chinese competitor CXMT and questions about the durability and financing of AI-driven demand. Traders are split between treating the pullback and rebound as a buying opportunity given the companys fundamentals and expecting further declines as selling pressure persists.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What Analyst Projections for Key Metrics Reveal About Thermo Fisher (TMO) Q3 Earnings

Besides Wall Street's top-and-bottom-line estimates for Thermo Fisher (TMO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2026.

If You Invested $1000 in Thermo Fisher Scientific a Decade Ago, This is How Much It'd Be Worth Now

Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.

Pfizer, Thermo Fisher Scientific And More: CNBC's 'Final Trades'

CNBC Final Trades: Weiss picked 10-year Treasuries, Thomas chose XAR, Firestone favored TMO, and Terranova selected PFE.read more...

Thermo Fisher Scientific (TMO) Reports Next Week: Wall Street Expects Earnings Growth

Thermo Fisher (TMO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is Adlai Nortye Ltd. Sponsored ADR (ANL) Stock Outpacing Its Medical Peers This Year?

Here is how Adlai Nortye Ltd. Sponsored ADR (ANL) and Thermo Fisher Scientific (TMO) have performed compared to their sector so far this year.

Thermo Fisher to Report Q3 Earnings: What's in the Cards?

TMO gears up for Q3 earnings, with revenue and EPS growth expected amid strong bioproduction demand, product innovations and clinical research strength.

Should You Add Abbott Stock to Your Portfolio Ahead of Q3 Earnings?

ABT's Q3 earnings are likely to have benefited from Diagnostics growth, Medical Device momentum and Nutrition innovations, while its valuation below historical levels draw investor interest.

All You Need to Know About Thermo Fisher (TMO) Rating Upgrade to Buy

Thermo Fisher (TMO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Is This the Right Time to Add TMO Stock to Your Portfolio?

Thermo Fisher's growth gains momentum through innovation, acquisitions and broad end-market strength, but macroeconomic and currency risks remain.

Zacks Industry Outlook Globus Medical, Intuitive Surgical  and Thermo Fisher Scientific 

Globus Medical, Intuitive Surgical  and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.


Thermo Fisher Scientific Inc. offers products and services to customers working in pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies. It operates through the following segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment provides reagents, instruments and consumables used in biological and medical research, discovery and production of new drugs and vaccines, and diagnosis of disease. The Analytical Instruments segment offers instruments and supporting consumables, software and services. The Specialty Diagnostics segment provides diagnostic test kits, reagents, culture media, instruments and associated products to healthcare, clinical, pharmaceutical, industrial, and food safety laboratories. The Laboratory Products and Biopharma Services segment offers outsourced services used by the pharmaceutical and biotech industries for drug development, clinical research, clinical trials services and commercial drug manufacturing. The company was founded in July 1956 and is headquartered in Waltham, MA.

Thermo Fisher Scientific Inc.

Thermo Fisher CEO Says AI Will Drive More Pharma Spending — Sees 7% Organic Growth By 2028

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>Casper said Thermo Fisher expects organic growth of about 4% in the second half of 2026.</li><li>The CEO said drugmakers could spend more to test promising medicines across more diseases.</li><li>Thermo Fisher has a partnership with OpenAI to speed up clinical trials and drug development.</li></ul>Thermo Fisher Scientific (TMO) CEO Marc Casper said artificial intelligence could ultimately increase spending across the pharmaceutical industry rather than reduce demand for laboratory research.In an interview with CNBC on Tuesday, Casper said AI is helping drugmakers identify ineffective drugs quicker while also accelerating the development of promising therapies.“AI is helping kill ineffective medicines faster, so that you don’t spend money on things that don’t work, and at the same point in time, shorten the time to market for those things that do work, and that gives you a longer return cycle on an improved medicine, and that will spur more investments,” Casper said.At the time of writing,&nbsp;<a href="https://stocktwits.com/symbol/TMO">TMO stock</a> was up 4%, heading for a third straight session of gains.<h2 class="st-heading-2">AI Could Spur More Drug Research Investments</h2>Casper pushed back on concerns that AI could reduce the need for laboratory experiments as drug research increasingly moves online.“So when you have more insights into what you do, you actually do a lot more validation, because what you’ll then do is spend more money on the ultimate number of indications or types of disease you’re going after with the medicine. So, AI - more spending, not less spending,” Casper addedThermo Fisher previously said AI could improve returns from drug discovery and encourage customers to invest more money into their pipelines. The company is also integrating AI into its operations, including a <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.thermofisher.com/investors/news-events/news/news-details/2025/Thermo-Fisher-Scientific-to-Accelerate-Life-Science-Breakthroughs-with-OpenAI/default.aspx?">collaboration</a> with OpenAI to speed up clinical trials and drug development.<h2 class="st-heading-2">Thermo Fisher’s 7% Organic Growth Target By 2028</h2>Casper said Thermo Fisher expects organic growth of about 4% in the second half of 2026 before accelerating to 7% by 2028. The outlook reflects improving momentum in the second quarter, when Thermo Fisher’s revenue <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.thermofisher.com/newsroom/press-releases/press-release-details/2026/Thermo-Fisher-Scientific-Reports-Second-Quarter-2026-Results/default.aspx">rose</a> 10% to $11.99 billion, with organic revenue up 5%.“I actually think the organic story, going forward, is very good,” Casper said.<h2 class="st-heading-2">Retail’s Take On TMO</h2>Retail sentiment surrounding TMO on Stocktwits remained in the ‘bearish’ zone over the past 24 hours.TMO shares have gained more than 9% in 2026.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/way-stock-surges-on-reported-sale-buzz-rbc-flags-this-tech-giant-as-the-obvious-first-name/cZtnWoERBc1">&nbsp;WAY Stock Surges On Reported Sale Buzz — RBC Flags This Tech Giant As The ‘Obvious First Name’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Thermo Fisher Scientific raised its full-year adjusted EPS guidance to a new range of $21.35 to $22.07 | Image Source: Thermo Fisher

In an interview with CNBC on Tuesday, Marc Casper said AI is helping drugmakers identify ineffective medicines quicker while also shortening the time to market for promising therapies.

$SPCX

$NFLX

$TSLA

$META

Which earnings release are you most looking forward to this week: $SPCX, $NFLX, $TSLA, or $META? Drop a comment for others.

Current Price	$679.38
Prev Close	$690.00
Open	$691.31
Dividend Yield	0.30%
50-Day Moving Average	$638.40
Beta	0.77
Avg. Volume	2.24M
PE Ratio	36.55

52-Week High	$704.00
52-Week Low	$435.27
Market Capitalization	$255.13B
EPS (Annual)	$17.74
Price to Book	4.77
Revenue Per Employee	$356,448.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

TMO Fundamentals